Ark Therapeutics signs manufacturing partnership agreement

Ark Therapeutics has announced a new manufacturing partnership with an unnamed European gene therapy company, which will aid the development of adenoviral-based medicines.

The master manufacturing services agreement with the prominent organisation will initially cover Ark's supply of manufacturing and development services, centring on its partner's therapeutic vaccine product.

Financial terms for the deal have not been disclosed, with Ark set to contribute its expertise in medicine development in addition to its state-of-the-art manufacturing capabilities.

This new agreement is indicative of Ark's new strategic efforts in the field of viral-focused contract development and manufacturing services.

Dr David Venables, Ark's executive director of manufacturing, said: "We are delighted to announce this substantive partnership which provides further validation of the strong scientific and technological capabilities available at Ark."

Earlier this month, the company announced the appointment of Dr Venables as its new chief executive officer, effective as of the beginning of next month.